YD Bio Limited

GRI Bio, Inc.

Supernus Pharmaceuticals, Inc.

Eikon Therapeutics, Inc.

Candel Therapeutics, Inc.

Compass Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Cartesian Therapeutics, Inc.

Annovis Bio, Inc.

Dilution score: 76/100 (CRITICAL), 10.9 months cash

13F fund flow: neutral, ? institutional managers

4 PubMed publications found for YD Bio Limited

Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results.

The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPD.

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.

Short interest: ?% of float, squeeze risk: LOW

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

<article class="bts-verified-summary" data-ticker="YDES">
<p>YD Bio Limited (YDES) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for YDES were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0002011674 (2026-06-17) <a href="https://efts.sec.gov/LATEST/search-index?q=%22YDES%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-05-18&amp;enddt=2026-06-17" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR — 0002011674

YD Bio Limited (YDES) — BioTechSigns Verified Summary

YD Bio Limited (YDES) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for YDES were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0002011674. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://efts.sec.gov/LATEST/search-index?q=%22YDES%22&forms=4&dateRange=custom&startdt=2026-05-18&enddt=2026-06-17